There are an estimated 300 million consultations in general practice in England annually (90% of all patient contacts with health care) ([@bib15]). A major challenge for primary-care clinicians is to discriminate, often on the basis of undifferentiated or non-specific symptoms, between patients with self-limiting illness and those with significant disease. Cancer symptoms typically have low positive predictive values and present a particular challenge in this respect ([@bib12]). Nevertheless, prompt identification and referral for investigation of patients with suspected cancer is a major public and policy concern ([@bib9]; [@bib22]), based on a widely held view that delays have a detrimental effect on outcome. The evidence is not as yet definitive. Although some studies have shown an association between longer time to diagnosis and poorer clinical outcomes ([@bib29]; [@bib35]), confounding by patients with advanced disease at presentation can make their interpretation problematic ([@bib26]). Meanwhile, prolonged time to diagnosis results in psychological distress and sub-optimal patient experience ([@bib30]; [@bib28]). Clinical guidance for general practitioners (GPs) on high-risk features warranting urgent referral for suspected cancer has been produced in a number of countries, and in England by NICE in 2005 ([@bib25]). Many cancer patients, however, present to their GP with lower-risk features ([@bib13]). A more recent approach to improving cancer outcomes in England has been to increase access for GPs to diagnostic tests supported by guidance on their use ([@bib10]).

In the 3 months before diagnosis, Danish patients with cancer have around 10 times as many diagnostic investigations as the reference population, some instigated by GPs ([@bib7]). Most studies of GPs\' use of investigations has addressed issues of test use ([@bib17]) and efficiency ([@bib37]; [@bib32]). It is uncertain, however, whether initial investigation of cancer symptoms in primary care delays referral for specialist assessment. This question is central to clinical practice and cancer diagnosis.

In order to answer the question of whether, in patients with symptoms suggestive of cancer, primary-care investigations are associated with less prompt referral, we analysed data from the English National Audit of Cancer Diagnosis in Primary Care, conducted during 2009/10 and containing information on 18 879 patients diagnosed with cancer in that period ([@bib31]).

Patients and methods
====================

The methods used in collection of the source data are described in detail elsewhere ([@bib31]). In brief, anonymous data were collected by GPs or other primary-care professionals in an estimated total of 1170 general practices (∼14% of all practices in England) that participated voluntarily in an audit of cancer diagnosis in primary care. All patients of those practices, who were diagnosed with cancer, typically during a defined period of up to 12 months, were included in the audit. Patients with screen-detected cancer, *in situ* cancer, and non-melanoma skin cancer were excluded. The age, gender, and cancer diagnosis case-mix of the audited population is representative of the population-based cancer incidence statistics, and participating practices are similar to non-participating practices in their (former) cancer networks ([@bib20]).

We analysed data on patients with lung (1494), colorectal (2111), stomach (246), oesophagus (513), pancreas (327), and ovarian (345) cancer. These six cancer sites were selected because they each have a range of presenting symptoms from high to low risk, and because for each there is one or more investigation that may be appropriately ordered as part of the patient\'s assessment in primary care and that is generally available to GPs in England.

We analysed data on patients aged 15 years or older with completely observed information on primary-care interval values from 0 to 730 days ([@bib21]). We defined primary-care interval as the period in days from first presentation to a GP with a relevant symptom to the date of first specialist referral for further assessment. The audit also collected the date of the first appointment with a specialist, but did not collect the date of diagnosis.

Gender and age were recorded from the patient medical records, the latter categorised for this study into six groups 15--44, 45--54, 55--64, 65--74, 75--4 and 85+.

Data were extracted from the audit data set in relation to two questions 'Did the GP order any investigations\' and 'If yes, please list the investigations in order\'. Practice staff were asked to identify any investigations undertaken prior to referral. Responses to the first question were coded as yes, no, or missing, and responses to the second question were used to create five binary variables coding whether or not the patient had had any of five common investigations: blood test; chest X-ray; ultrasound scan; CT or MRI scan; endoscopic investigation.

Clinical presentation
---------------------

Free text audit records in response to the question 'What was the main presenting symptom?\' were categorised in two stages. First, and separately by cancer, the presenting symptom(s) was classified into between 20 and 37 groups ([Appendix Table A1](#app1){ref-type="app"}). These were agreed by three clinicians (GPR, RDN, GL) and then independently assigned by them. Disagreements were resolved by discussion between coders. Where more than one symptom was described, the main symptom was taken as the first stated, unless a NICE Clinical Guideline (CG)27-mandated ('alarm\') symptom appeared later in the list.

Second, patients were classified on the basis of their presenting symptom(s) and age into five groups according to CG27; mandated referral; possibly mandated referral (insufficient information provided on qualifying conditions (e.g., severity, duration, frequency) to be definitive); mandated investigation; possibly mandated investigation (as above); no mandated action. Some presenting symptoms (e.g., ascites, haematemesis) were not specifically mentioned in CG27 as requiring urgent referral, but the clinical consensus was that this would be best practice. These were included in the 'mandated referral\' group. Coding was age specific for those symptoms for which CG27 recommendations were age-conditional. For multivariable analysis, 'possible referrals\' were grouped with 'no action\' for ovarian and oesophageal cancers because of small numbers.

Statistical analysis
--------------------

We describe the primary-care interval distribution using the mean, median, 25th, 75th, and 90th centiles. Stratified by cancer diagnosis, we calculated the percentages of patients investigated by their GP in each of the five NICE CG27 referral recommendation groups.

We calculated the mean difference in primary-care interval among those patients investigated in primary care and those who were not. To determine whether the association between primary-care investigations and primary-care interval can be attributed to different clinical presentations (i.e., whether patients who are most likely to be investigated are simply those who present with non-specific symptoms and have a longer primary-care interval for this reason), we used linear regression to estimate the mean difference in primary-care interval by investigation status, adjusting for age, gender, and the NICE referral category, separately by cancer.

95% Confidence intervals were estimated using bias corrected and accelerated bootstrap estimation, and where they exclude zero, the differences between the two groups were taken to be significant at *P*\<0.05. Analyses were repeated for 99.99% confidence intervals.

We performed a number of sensitivity analyses investigating the impact of how the primary-care interval, primary-care investigation use and clinical presentation were parameterised (see [Appendix Tables](#app1){ref-type="app"} for details). Further, we performed a supplementary analysis to explore the possibility that primary-care investigation may decrease the referral interval (defined as the number of days between referral from primary care and first patient contact in secondary care). We therefore explored the adjusted association of overall pre-hospital interval (defined as the total time from first presentation to primary care to first being seen in secondary care, i.e., referral interval plus primary-care interval) with investigation use.

Results
=======

The derivation of the analysis sample is shown in [Figure 1](#fig1){ref-type="fig"}. In descriptive analyses, primary-care investigations were undertaken in 3198/5036 of included cases (64%), ranging from 43% for oesophageal cancer to 80% for lung cancer. The median primary-care interval across all six cancer sites was 16 (IQR 5--45) days for those who had one or more investigation, and 0 (IQR 0--10) days for those who had no investigation. The corresponding mean intervals were 41 days and 17 days, and did not differ by age or gender. The difference in the median interval by investigation status was considerably greater at the 75th (10 days non-investigated, 44 days investigated patients) and 90th centiles (45 days and 106 days, respectively) ([Table 1](#tbl1){ref-type="table"}).

In unadjusted analyses, individual investigations lengthened the mean primary-care interval by between 5 days (chest X-ray) and 32 days (endoscopy), whereas undertaking more than one test in primary care added a mean of 8 days ([Table 2](#tbl2){ref-type="table"}). For individual cancer sites, any investigation significantly extended the mean primary-care interval by between 20 days (ovarian) and 30 days (stomach) ([Table 2](#tbl2){ref-type="table"}). When individual cancers were considered by NICE referral category, investigation was more likely if NICE CG27 mandated this or if no action was mandated. The proportion of patients presenting with symptoms for which NICE CG27 mandates urgent referral was 10%, 9%, 5%, 64%, 24%, and 37% for colorectal, ovarian, lung, oesophageal, pancreatic, and stomach cancer, respectively. Nevertheless, a substantial proportion of patients whose symptoms mandated urgent referral were investigated in primary care, ranging from 37% (oesophagus) to 75% (pancreas) ([Table 3](#tbl3){ref-type="table"}).

In linear regression analyses, stratified by cancer, that adjusted for age, sex, and the NICE referral category, adjustment for these factors explained very little of the mean observed additional days associated with investigation, but the effect for pancreatic cancer ceased to be significant ([Table 4](#tbl4){ref-type="table"}). Alternative parameterisations of the primary-care interval, investigation use, or clinical presentation categories made minimal difference to these findings ([Appendix Tables A3--A5](#app1){ref-type="app"}).

Among those patients for whom data on number of consultations prior to referral were available, 965/2095 (46.1%) of those consulting once were investigated, while 1058/1240 (85.3%) of those consulting 3+ times were investigated.

Finally, in order to address the possibility that longer primary-care intervals might be offset by shorter referral intervals, we examined the association between investigations in primary care and the combined primary care and referral interval (i.e., from first presentation in primary care to first being seen in a specialist clinic). For all cancers, except pancreatic cancer, the pre-hospital interval is longer among investigated patients, compared with those who were not investigated. We find no evidence that longer primary-care intervals are offset by shorter referral intervals in patients who are investigated in primary care ([Appendix Table A6](#app1){ref-type="app"}). Because date of diagnosis did not form part of the data items collected for the audit, we were unable to examine the effect of investigations on total diagnostic interval.

Discussion
==========

We found that for six specified cancers, investigation in primary care of the presenting symptom(s) was associated with later referral for specialist assessment. This difference in the mean primary-care interval ranged from an additional 20 to 30 days depending on the cancer site, and was independent of whether the patient presented with alarm symptoms. For four of the six cancers studied, the difference increased with the number of tests undertaken.

The principle that patients with symptoms are initially assessed in primary care in order that only a proportion are then more extensively assessed by specialists (the gatekeeping function) is a key feature of health-care systems in which primary care features strongly. It contributes to their better health outcomes and efficiencies ([@bib34]), although an ecological association with poorer cancer 1-year survival has also been described ([@bib36]). Investigation in primary care is most strongly associated with perceived medical need, although a minority of investigations are a consequence of patient preference ([@bib19]). Where the alternative is specialist referral, investigation in primary care may result in the primary-care interval being prolonged, since additional consultations are needed to communicate results, and multiple consultations are associated with longer primary-care intervals ([@bib21]). We found that 85% of patients consulting three or more times had undergone investigation, compared with 46% of those consulting once. The literature is sparse on the effect of investigations in primary care on time to diagnosis, although a study of patients with colorectal cancer found that those who were not investigated by the faecal occult blood test had a significantly shorter median diagnostic interval than those who were ([@bib16]). Further, a qualitative study of patients with testicular cancer identified waiting time for GP-requested ultrasonography as a factor in late diagnosis ([@bib5]). However, failure to investigate may be also associated with referral being deferred. In a study of GP-reported quality deviations in 5711 patients with cancer, failure to order relevant investigations was associated with a prolonged diagnostic interval ([@bib18]), whereas diagnostic delay for tuberculosis has been associated with failure of the first doctor consulted to order a sputum test or chest X-ray ([@bib4]).

Strategies have been developed to expedite the investigation of patients with symptoms that could indicate cancer. In Denmark, ambulatory care facilities exist for the prompt investigation of patients with non-specific symptoms, alongside an urgent referral pathway for those with higher-risk symptoms ([@bib8]) Walk-in access to chest X-ray for symptomatic members of the public aged \>50 years has been provided through a local initiative in Leeds, UK, resulting in 8.6% of all community-ordered chest X-rays being taken this way ([@bib6]). Dedicated centres that allow patients to access specialist assessment without physician referral have also been proposed by a panel of cancer experts in the United States, as a response to their Institute of Medicine report 'Crossing the Quality Chasm\' ([@bib3]). The initiatives described address a range of constraints to prompt diagnosis, and they operate within complex health systems. Their impact can only be fully understood in the context of the overall diagnostic pathway, something we were unable to do in this study.

Strengths and limitations
-------------------------

This is the first study to explicitly determine the effect of GP-initiated investigations on speed of referral for specialist assessment. Its strengths include the relatively large number of cases for each cancer site, the completeness of data on presenting symptom(s) and consultations, and the direct extraction of information from the primary-care record. The study team included experienced clinicians, ensuring that the complex task of coding clinical data was accurately completed.

There are several limitations that we acknowledge. Because participation of general practices in the audit was voluntary and potentially biased towards those most interested in cancer care, the findings may represent 'better\' practice. However, the audit patient population was similar to the incident cancer cases in England ([@bib31]) while the characteristics of participating practices were similar to non-participating practices of the same (former) cancer network ([@bib21]). Nevertheless, these practices may have been more interested in cancer diagnosis and management and more likely to investigate patients with suspicious symptoms. Practices were typically required to audit a continuous sample of cases occurring in a specified period, and there was no evidence of significant exclusion of cases ([@bib31]).

Data were extracted from clinical records and hospital correspondence. There was no validation of the data, but in all cases data were reviewed at a practice meeting and checked for completeness and face validity by a cancer network clinical lead. There is scope for errors of interpretation during data extraction, for example, in deciding on the date of first consultation. The potential sources of error in studies of diagnostic intervals have been well described ([@bib38]), but the methodology used by the audit conformed to best practice in the field [@bib38]). Finally, 1100 (17.9%) cases were excluded because both of the dates required to estimate the primary-care interval were not available. Many of these were patients whose pathway to diagnosis bypassed primary care, for example, through direct presentation to an emergency department. Others may have been seen by the GP, but the omission of dates of the first encounter and/or referral was not identified during the checking process prior to submission of data to the audit.

All investigations included were part of the primary-care appraisal process, but no judgement was made on their appropriateness or their context within the episode of care. It is possible that some were unhelpful or irrelevant to the diagnostic process and unnecessarily prolonged the primary-care interval. Details of the precise nature of blood or urine tests or the sites examined by CT, MRI, or endoscopy were not a specific requirement of practices participating in the audit.

Because the audit data were provided in an anonymous form, we were unable to link them to cancer registration and hospital record-derived data. This would have allowed us to determine, for those patients not investigated in primary care, whether investigation(s) were then undertaken in secondary or tertiary care and the effect of investigations in different settings on the total diagnostic interval. However, we observed that use of investigations, although adding to the length of the primary-care interval, did not result in a shorter referral interval. Moreover, for the hypothesis to be true that patients investigated in primary-care experience shorter secondary-care delays, and therefore no overall lengthening of the total diagnostic interval, either or both of the referral interval and the within-hospital interval to diagnosis would need to be substantially shorter for those patients with primary-care investigations compared with those without. These conditions are unlikely. First, we have observed a net lengthening of referral interval resulting from investigations for five out of six cancers. Second, as use of investigations is associated with extending of the primary-care interval by a median of +16 days and a mean of +24 days, within-hospital diagnostic processes would need to be extraordinarily fast to compensate for these prolonged intervals. It should also be noted that in 2011/12 87.3% of patients commenced treatment within 62 days of referral, and 98.4% commenced treatment within 31 days of a diagnosis being made ([@bib11]). Moreover, the most frequent primary-care investigations were blood tests and chest X-rays, tests that do not typically provide the definitive diagnostic information necessary to establish the diagnosis of cancer, and would be unlikely to result in any substantial shortening of diagnostic intervals within secondary or tertiary care.

We selected the NICE referral category as our primary method for categorising patients\' presenting symptoms. We adjusted for symptom status using a range of complementary analytical approaches, all of which indicated that the degree of confounding by symptom status (in respect of the association between investigation and prolonged primary-care interval) is trivial. In other words, whether patients present with non-specific symptoms or obvious alarm symptoms, investigations are always associated with a longer primary-care interval.

Implications for practice
-------------------------

Our findings are generalisable to health systems in which GPs act as gatekeepers to specialist care, but may be modified by differences in access to diagnostic tests. A substantial proportion of patients underwent investigation when their symptoms fulfilled NICE CG27 criteria for urgent referral. There are several possible explanations for this. Disparaging views from specialists about 'abuse\' by GPs of the urgent referral pathway may make some prefer to have additional evidence in the form of a confirmatory test result before making a referral ([@bib23]). The NICE criteria typically represent a risk of cancer in the region of 5--10%, the large majority not having the disease, and some GPs may use investigations as means of increasing the probability of cancer prior to making a decision about referral. It is also possible that some patients present in a context that causes the GP to modify their preferred course of action. For example, the patient may have been investigated in the past for the same problem, have severe co-morbidities, or may be reluctant to be referred to a specialist. Some GPs may consider it desirable, or have been advised that it is, for the results of baseline investigations to be available at the first specialist attendance ([@bib2]). Significant event analyses and case-note review studies are required to further establish the circumstances surrounding such 'guideline violations\' ([@bib24]; [@bib33]).

Finally, certain investigations available to GPs are the definitive diagnostic tests, e.g., gastroscopy for suspected oesophagogastric cancer, and may be as readily available in primary as in specialist care. Other diagnostic tests, however, take longer to complete when ordered from primary care and may not be sufficiently comprehensive. In England, the median time from request to test for non-obstetric ultrasound investigation is longer for GP requests (19--27 days) than for all request sources combined (12--16 days) ([@bib27]). If investigations are undertaken in patients for whom urgent referral is indicated, the request should be concurrent with referral.

Because tests ordered in primary care may not be done or reported as promptly as those ordered from secondary care, our findings point to a need for investigative services to be provided to a comparable standard regardless of source of request. This should be accompanied by improved systems in primary care that ensure that a patient is rapidly reviewed once results are received. They also provide some support for models of service delivery in England that permit the rapid specialist assessment of patients with lower-risk symptoms, either by a lowering of the thresholds for urgent (2 weeks) referral for suspected cancer or the provision of diagnostic centres.

Time may be used as a diagnostic tool in primary care ([@bib14]). Symptoms are seen by GPs at an earlier stage of development than in secondary care, and time allows the clinician to observe whether relatively undifferentiated symptoms develop more specific characteristics or resolve spontaneously. Investigations may form a part of this temporising approach while also being part of a safety-netting strategy ([@bib1]).

These findings are the first step in determining the most effective diagnostic strategies for managing patients with symptomatic presentation of cancer. It will be important to understand the impact of primary-care investigation on secondary-care intervals, since these may plausibly be shortened, and on total diagnostic delay. Until then, no firm recommendations can be made on the merits or demerits of primary-care investigation. There is a need to understand the comparative clinical and health economic efficiency of strategies that encourage early primary-care investigation, compared with those that encourage either expectant management with limited testing and urgent referral if symptoms persist or worsen, or early referral without prior investigation.
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Sensitivity analysis
====================

We performed several sensitivity analyses for key analytical aspects, using alternative parameterisations of the three variables: Primary-care intervalInvestigation use in primary careClinical presentation

Primary-care interval is positively skewed, with a large number of zero values. The analysis (presented in the main text) examines 'mean differences\' in primary-care interval associated with investigation use. Although the use of bootstrap estimation means that inference is appropriate, we also performed a sensitivity analysis based on a binary categorisation of primary-care interval into 0--14 and 15+ days. Results are presented in Appendix [Table A3](#tblA3){ref-type="table"}.

Investigation use can be parameterised as a binary yes/no variable (as in the main text)---or as an ordered categorical variable based on the number of investigations (used in sensitivity analysis). Specifically, the number of investigations was parameterised as an ordered categorical variable (0, 1, 2 or more investigations) based on counts of the five individual investigations (blood tests, chest X-rays, ultrasound, CT/MRI, or endoscopy). Results are presented in Appendix [Table A4](#tblA4){ref-type="table"}.

In the main analysis presented, we adjust for clinical presentation using five groups based on NICE guideline referral categories (Appendix [Table A2](#tblA2){ref-type="table"}). In sensitivity analysis adjustment for clinical presentation was made on the basis of presenting symptom(s) (Appendix [Table A1](#tblA1){ref-type="table"}) and based on this classification, but allowing the effect of symptom to vary by age. We also explored adjusting for the more detailed 14-group classification based on NICE guidelines ([Appendix Table A2](#tblA2){ref-type="table"}). Results are [](#tblA5){ref-type="table"}presented in [Appendix Table A6](#tblA6){ref-type="table"}.

**Supplementary analysis**

We performed a supplementary analysis to explore the possibility that primary-care investigation may decrease the referral interval (defined as the number of days between referral from primary care and the first patient contact in secondary care). If this hypothesis were true, it might offset the differences in primary-care interval. We therefore explored the adjusted association of overall pre-hospital interval (defined as the total time from first presentation to primary care to first being seen in secondary care, i.e., referral interval plus primary-care interval) with investigation use. Results are presented in [Appendix Table A6](#tblA6){ref-type="table"}.

For ovarian and oesophageal cancers 'possible referrals\' were grouped with 'no action\' in multivariable analysis because of small numbers, similarly age 15--44 years is grouped with age 55--64 years for pancreatic cancer because of small numbers.

In order to address the possibility that longer primary-care intervals might be offset by shorter referral intervals among investigated patients, we examined the association between investigations in primary care and the referral interval, and the combined primary care and referral interval (i.e., from first presentation in primary care to first being seen in a specialist clinic).

Although the differences in referral interval among investigated and non-investigated patients are small they are positive for all cancers except for pancreatic (i.e., referral intervals are not shorter among investigated patients). Consequently, the pre-hospital interval is longer among investigated patients, compared with those who were not investigated for all cancers except pancreatic cancer. Therefore, overall there is no evidence that longer primary-care intervals are offset by shorter referral intervals among patients who were investigated in primary care.
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###### Patient characteristics, mean and median (percentile) primary-care interval

                                              **Primary-care interval**                  
  ------------------------------------ ------ --------------------------- ----- --- ---- -----
  **All**                              5036   32.5                        8     0   34   87
  **Sex**                                                                                
  Female                               2413   33.1                        9     0   36   88
  Male                                 2623   31.9                        8     0   32   85
  **Age**                                                                                
  15--44                               150    36.9                        7.5   0   43   113
  45--54                               405    30.3                        8     0   34   75
  55--64                               1030   31.1                        8     0   33   85
  65--74                               1503   32.0                        8     0   34   83
  75--84                               1430   33.6                        9     0   36   88
  85+                                  518    34.2                        7     0   32   100
  **Cancer diagnosis**                                                                   
  Colorectal                           2111   33.0                        6     0   30   94
  Ovarian                              345    21.5                        7     0   25   54
  Lung                                 1494   34.5                        13    3   39   83
  Oesophageal                          513    26.3                        6     0   31   75
  Pancreatic                           327    33.0                        7     0   32   96
  Stomach                              246    43.2                        13    0   58   132
  **Investigations in primary care**                                                     
  No                                   1838   17.4                        0     0   10   44
  Yes                                  3198   41.2                        16    5   45   106

###### Primary-care investigations and primary-care interval, by cancer

                                                                                   **All**   **Colorectal**   **Ovarian**   **Lung**   **Oesophageal**   **Pancreatic**   **Stomach**                                                                                          
  ----------------------------------------------- ------------------------------- --------- ---------------- ------------- ---------- ----------------- ---------------- ------------- ------ ------ ------ ------ ------ ----- ------ ------ ----- ------ ----- ----- ------- ------
  Any investigation in primary care                No[a](#t2-fn2){ref-type="fn"}    1838          17.4             0          967           18.6               0              105      7.5    0       294    17.1    1     293   15.5    0     81    15.5    0    98    24.9     0
                                                                Yes                 3198          41.2            16          1144          45.3               17             240      27.7   13      1200   38.9    16    220   40.7    21    246   38.8   13    148   55.3     22
  Blood test                                                    No                  2996          26.3             4          1140          23.4               1              195      19.5   2       1058   32.6    11    350   19.4    1     122    23     0    131   32.7     2
                                                                Yes                 2040          41.6            15          971           44.4               16             150      24.1   13      436    39.5    17    163   41.2    21    205    39    12    115   55.2     21
  Chest X-ray                                                   No                  3908          31.4             6          2070           33                6              327      21.1   7       464    31.9    7     494   25.9    4     314   31.5    7    239   42.8     12
                                                                Yes                 1128          36.2            16           41           36.3               12             18       29.2   15.5    1030   35.8    15    19     37     27    13    68.9   39     7    56.6     19
  Ultrasound                                                    No                  4546          30.9             7          1979          31.8               5              186      14.4   2       1455   34.3    13    497   25.3    5     211   20.8    3    218   35.7     9
                                                                Yes                  490          47.7            20          132           50.8              21.5            159      29.9   14       39    44.3    22    16    56.8    33    116   55.3   21    28    101.5    57
  CT/MRI                                                        No                  4928          31.9             8          2094          32.5               6              338      20.9   7       1420   33.6    12    511   26.3    6     320   33.2    7    245   43.4     13
                                                                Yes                  108          56.9            35           17           95.1               39              7       54.1   34       74    52.9    35     2    20.5   20.5    7     26    13     1      5      5
  Endoscopy                                                     No                  4861          31.4             8          2022          31.1               5              341      21.7   7       1484   34.4    13    478   25.1    5     314   30.8    7    222   43.5     12
                                                                Yes                  175          63.1            20           89           76.7               20              4       7.5    7.5      10    56.4   40.5   35    43.2    15    13    86.7   49    24    40.5    19.5
  Count of any of the above five investigations    0[a](#t2-fn2){ref-type="fn"}     1952          19.5             0          1031           20                0              108      8.3    0       312    22.4    2     315   17.7    0     82    15.9    0    104   25.9    0.5
                                                                 1                  2301          38.7            14          923           42.4               14             147      30.1   11      809    37.7    14    162   37.3    15    148   22.9   7.5   112   49.4     23
                                                                2+                   783          46.9            21          157           63.9               23             90       23.3   14      373    38.1    20    36    52.1   32.5   97     63    22    30    79.8     21

Abbreviations: CT=computed tomography; MRI=magnetic resonance tomography.

The numbers in these two groups are slightly different as the first two rows include patients who have had any investigation in primary care, but the bottom three rows are counts based only on the five listed investigations (blood tests, chest X-rays, ultrasound, CT/MRI, or endoscopy).

###### Use of primary-care investigations and the NICE guideline referral category based on clinical presentation, by cancer

                                                                                             **GP investigations performed**   
  ------------- --------------------------------------------------------------------- ------ --------------------------------- ------
  Colorectal    Mandated referral under NICE guidelines (or good clinical practice)   208    99                                47.6
                Possible referral under NICE guidelines                               1105   581                               52.6
                Mandated investigation under NICE guidelines                          200    90                                45.0
                Possible investigation under NICE guidelines                          0                                         
                No action under NICE guidelines                                       598    374                               62.5
  Ovarian       Mandated referral under NICE guidelines (or good clinical practice)   31     12                                38.7
                Possible referral under NICE guidelines                               5      0                                  
                Mandated investigation under NICE guidelines                          26     16                                61.5
                Possible investigation under NICE guidelines                          0                                         
                No action under NICE guidelines                                       283    212                               74.9
  Lung          Mandated referral under NICE guidelines (or good clinical practice)   76     39                                51.3
                Possible referral under NICE guidelines                               0                                         
                Mandated investigation under NICE guidelines                          223    195                               87.4
                Possible investigation under NICE guidelines                          916    779                               85.0
                No action under NICE guidelines                                       279    187                               67.0
  Oesophageal   Mandated referral under NICE guidelines (or good clinical practice)   328    121                               36.9
                Possible referral under NICE guidelines                               9      0                                 0.0
                Mandated investigation under NICE guidelines                          0                                         
                Possible investigation under NICE guidelines                          69     36                                52.2
                No action under NICE guidelines                                       107    63                                58.9
  Pancreatic    Mandated referral under NICE guidelines (or good clinical practice)   79     59                                74.7
                Possible referral under NICE guidelines                               100    65                                65.0
                Mandated investigation under NICE guidelines                          0                                         
                Possible investigation under NICE guidelines                          0                                         
                No action under NICE guidelines                                       148    122                               82.4
  Stomach       Mandated referral under NICE guidelines (or good clinical practice)   92     45                                48.9
                Possible referral under NICE guidelines                               21     15                                71.4
                Mandated investigation under NICE guidelines                          0                                         
                Possible investigation under NICE guidelines                          40     26                                65.0
                No action under NICE guidelines                                       93     62                                66.7

Abbreviations: GP=general practitioner; NICE=National Institute for Health and Care Excellence.

###### Mean additional length of primary-care interval associated with primary-care investigations after adjustment for age, sex and NICE guideline referral category

                                                                      **Mean additional primary-care interval (in days) among patients where investigations were performed**                      
  ---------------------------------------- ------------------ ------ -------------------------------------------------------------------------------------------------------- ------------------- -------------
  Colorectal                               Not investigated   967                                                   Reference                                                      Reference       *P*\<0.0001
                                           Investigated       1144                                              26.7 (20.8--33.0)                                              25.7 (19.5--31.7)         
  Ovarian[b](#t4-fn3){ref-type="fn"}       Not investigated   105                                                   Reference                                                      Reference       *P*\<0.0001
                                           Investigated       240                                               20.1 (13.6--27.5)                                              18.4 (12.2--25.5)         
  Lung                                     Not investigated   294                                                   Reference                                                      Reference       *P*\<0.0001
                                           Investigated       1200                                              21.8 (15.3--27.6)                                              23.6 (16.8--30.0)         
  Oesophageal[b](#t4-fn3){ref-type="fn"}   Not investigated   293                                                   Reference                                                      Reference       *P*\<0.0001
                                           Investigated       220                                               25.3 (16.7--34.8)                                              22.3 (13.2--32.4)         
  Pancreatic^c^                            Not investigated   81                                                    Reference                                                      Reference        *P*\>0.05
                                           Investigated       246                                                23.2 (5.0--38.1)                                              17.1 (−1.9--30.6)         
  Stomach                                  Not investigated   98                                                    Reference                                                      Reference       *P*\<0.0001
                                           Investigated       148                                               30.4 (15.1--48.2)                                              29.3 (14.0--45.8)         

Abbreviation: NICE=National Institute for Health and Care Excellence.

95% Confidence intervals were estimated using bias corrected and accelerated bootstrap. The *P*-value (*P*\>0.05) presented for pancreatic cancer reflects that this 95% confidence interval crosses zero. For all other cancers bias corrected and accelerated bootstrap 99.99%confidence intervals were re-estimated for the same model and these also did not cross zero, *P*\<0.0001 is correspondingly presented.

'Possible referrals\' grouped with 'No action\' in multivariable analysis because of small numbers.

Age 15--44 years grouped with age 55--64 years because of small numbers.

###### Symptom groups by cancer

  **Oesophageal and gastric cancer**    **Lung cancer**                                         **Ovarian cancer**                                                         **Colorectal cancer**                                **Pancreatic cancer**
  ------------------------------------- ------------------------------------------------------- -------------------------------------------------------------------------- ---------------------------------------------------- -------------------------------------------------------------------------
  Dysphagia                             Haemoptysis                                             Ultrasound suggestive of ovarian cancer                                    Rectal bleeding                                      Obstructive jaundice
  Early satiety                         Chest/shoulder pain                                     Post-menopausal bleeding                                                   Altered bowel habit (to looser stool)                Thromboembolic disease
  Nausea, vomiting                      Dyspnoea                                                Persistent intermenstrual bleeding (with a negative pelvic examination)    Abdominal mass                                       Bleeding per rectum/melaena
  Dyspepsia                             Weight loss                                             Abdominal or pelvic mass not of gastroenterological or urological origin   Rectal mass                                          Diabetic ketoacidosis/new onset diabetes/loss of known diabetes control
  Reflux                                Chest signs                                             Abdominal or pelvic pain or discomfort                                     Anaemia                                              Altered bowel habit
  Pain (epigastric, abdominal, chest)   Hoarseness                                              Abdominal bloating/distension/swelling/fullness                            Weight loss                                          Nausea and vomiting
  Anorexia                              Clubbing                                                Urinary symptoms (including incontinence and retention)                    Abdominal pain or tenderness                         Gastro-oesophageal reflux disease
  Fatigue, malaise                      Chest X-ray/supraclavicular lymph nodes                 Unexplained weight loss                                                    Bloating/distension                                  General malaise
  Weight loss                           Cough                                                   Fatigue/tiredness/malaise/unwell/exhaustion                                Malaise                                              Bloating
  Bowel disturbance                     Features suggesting metastases                          Change in bowel habit to diarrhoea or alternating diarrhoea/constipation   Asymptomatic or incidental, including surveillance   Biliary colic
  Iron deficiency anaemia               Abnormal chest X-ray                                                                                                               Acute surgical/medical emergency                     Cough/shortness of breath
  Haematemesis/melaena                  Superior vena cava obstruction                          Vaginal discharge or other abnormal vaginal bleeding                       Constipation                                         Weight loss
  Dizziness                             Stridor                                                 Anaemia                                                                    Nausea/vomiting                                      Urinary tract infection/other urinary symptoms
  Upper abdominal mass                  Loss of appetite                                        Chest symptoms                                                             Other pain                                           anaemia
  Asymptomatic or incidental finding    Thrombocytosis                                          Pulmonary embolus or deep vein thrombosis                                  Defaecation problems                                 Back pain
  Pain (other)                          Abnormal spirometry                                     Infertility                                                                Anorexia                                             Abdominal pain
  Barrett\'s                            Asymptomatic or incidental                              Nausea and/or vomiting                                                     Mucus                                                Abdominal mass
  Respiratory symptoms                  Hyponatraemia                                           Asymptomatic or incidental                                                 Collapse                                             Asymptomatic or incidental
  Bloating                              Respiratory infection                                   Ascites                                                                    Respiratory symptoms                                 Anorexia
  Belching                              Exacerbation of chronic obstructive pulmonary disease   Anorexia                                                                   Haemorrhoids                                         Dysphagia
  Throat symptoms                       Abdominal pain                                          Other/missing/not stated/not known                                         Urinary symptoms                                     Change in bowel habit
  Hiatus hernia                         Back pain                                                                                                                          Liver                                                Dyspepsia
  Odynophagia                           Liver symptoms/signs                                                                                                               Upper gastrointestinal symptoms                       
  Other/missing/not stated/not known    Confusion                                                                                                                          Disordered sensation lower limbs                     Liver
                                        Malaise                                                                                                                            Ascites                                              Pancreatitis/chronic
                                        Collapse                                                                                                                           Colitis/inflammatory bowel disease                   Steatorrhoea
                                        Change in bowel habit                                                                                                              Other/missing/not stated/not known                   Lymphadenopathy
                                        Pain (other)                                                                                                                                                                            Other/missing/not stated/not known
                                        Urinary symptoms                                                                                                                                                                         
                                        Headache                                                                                                                                                                                 
                                        Lower limb oedema                                                                                                                                                                        
                                        Sweats/fever                                                                                                                                                                             
                                        Anaemia                                                                                                                                                                                  
                                        Upper gastrointestinal symptoms                                                                                                                                                          
                                        Lump                                                                                                                                                                                     
                                        Nausea or vomiting                                                                                                                                                                       
                                        Cardiac abnormalities                                                                                                                                                                    
                                        Neurological                                                                                                                                                                             
                                        ENT symptoms                                                                                                                                                                             
                                        Other/missing/not stated/not known                                                                                                                                                       

Abbreviation: ENT=ear, nose and throat.

###### NICE guideline referral categories based on clinical presentation

  --------------------------------------------------------------------- ----------------------------------------------------------------------------------------------
  Mandated referral under NICE guidelines (or good clinical practice)   Clear evidence for mandated urgent referral as per NICE CG27
                                                                        Good clinical medicine would mandate urgent referral
  Possible referral under NICE guidelines                               Possible mandated urgent referral as per NICE CG27---but duration dependent
                                                                        Possible mandated urgent referral as per NICE CG27---but severity dependent
                                                                        Possible mandated urgent referral as per NICE CG27---but location dependent
                                                                        Possible mandated urgent referral as per NICE CG27---but dependent upon sense of abnormality
                                                                        Possible mandated urgent referral as per NICE CG27---other
  Mandated investigation under NICE guidelines                          Clear evidence of mandated investigation as per NICE CG27
  Possible investigation under NICE guidelines                          Possible mandated investigation as per NICE CG27---but duration dependent
                                                                        Possible mandated investigation as per NICE CG27---but severity dependent
                                                                        Possible mandated investigation as per NICE CG27---but location dependent
                                                                        Possible mandated investigation as per NICE CG27---but dependent upon sense of abnormality
                                                                        Possible mandated investigation as per NICE CG27---other
  No action under NICE guidelines                                       No mandated action from NICE CG27
  --------------------------------------------------------------------- ----------------------------------------------------------------------------------------------

Abbreviation: NICE=National Institute for Health and Care Excellence.

###### Sensitivity analysis using alternative parameterisation of primary-care interval

                                   **Number of cases**    **Adjusted for age, sex, and the NICEreferral category based on presenting symptoms**   **OR (95% CI) for 15+ days primary-care interval (compared with 0--14 days) adjusted for age, sex, and clinical presentation**   ***P*****-value**
  ------------- ------------------ --------------------- --------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------- -------------------
  Colorectal    Not investigated   967                                                       ***Reference***                                                                                                Reference                                                                   \<0.001
                Investigated       1144                                         ***25***.***7 (19***.***5--31***.***7)***                                                                                 4.6 (3.7--5.6)                                                                    
  Ovarian       Not investigated   105                                                       ***Reference***                                                                                                Reference                                                                   \<0.001
                Investigated       240                                          ***18***.***4 (12***.***2--25***.***5)***                                                                                 4.2 (2.3--7.9)                                                                    
  Lung          Not investigated   294                                                       ***Reference***                                                                                                Reference                                                                   \<0.001
                Investigated       1200                                         ***23***.***6 (16***.***8--30***.***0)***                                                                                 3.8 (2.8--5.2)                                                                    
  Oesophageal   Not investigated   293                                                       ***Reference***                                                                                                Reference                                                                   \<0.001
                Investigated       220                                          ***22***.***3 (13***.***2--32***.***4)***                                                                                 4.1 (2.8--6.1)                                                                    
  Pancreatic    Not investigated   81                                                        ***Reference***                                                                                                Reference                                                                   \<0.001
                Investigated       246                                          ***17***.***1 (−1***.***9--30***.***6)***                                                                                 4.4 (2.1--9.2)                                                                    
  Stomach       Not investigated   98                                                        ***Reference***                                                                                                Reference                                                                   \<0.001
                Investigated       148                                          ***29***.***3 (14***.***0--45***.***8)***                                                                                5.7 (3.1--10.6)                                                                    

Abbreviations: CI=confidence interval; NICE=National Institute for Health and Care Excellence; OR=odds ratio.

Results presented in bold italics are those from [Table 4](#tbl4){ref-type="table"}

This sensitivity analysis finds that investigation use is associated with longer primary-care interval for all six cancers when using a logistic model.

###### Sensitivity analysis using alternative parameterisation of investigation use in primary care

                                      **Number of cases**    **Adjusted for age, sex, and the NICE referral category based on presenting symptoms**                         **Number of cases**    **Adjusted for age, sex, and the NICE referral category based on presenting symptoms**
  ------------- --------------------- --------------------- ---------------------------------------------------------------------------------------- ---------------------- --------------------- ----------------------------------------------------------------------------------------
  Colorectal    Not investigated^a^   967                                                       ***Reference***                                      No investigations^a^   1031                                                         Reference
                Investigated          1144                                         ***25***.***7 (19***.***5--31***.***7)***                         One                    923                                                      21.3 (15.1--30.0)
                                                                                                                                                     Two+                   157                                                      43.5 (28.3--58.2)
  Ovarian       Not investigated      105                                                       ***Reference***                                      No investigations      108                                                          Reference
                Investigated          240                                          ***18***.***4 (12***.***2--25***.***5)***                         One                    147                                                      20.1 (11.0--30.6)
                                                                                                                                                     Two+                   90                                                        13.6 (6.0--21.2)
  Lung          Not investigated      294                                                       ***Reference***                                      No investigations      312                                                          Reference
                Investigated          1200                                         ***23***.***6 (16***.***8--30***.***0)***                         One                    809                                                       17.0 (6.9--24.7)
                                                                                                                                                     Two+                   373                                                       16.2 (6.6--24.8)
  Oesophageal   Not investigated      293                                                       ***Reference***                                      No investigations      315                                                          Reference
                Investigated          220                                          ***22***.***3 (13***.***2--32***.***4)***                         One                    162                                                       17.1 (7.7--28.8)
                                                                                                                                                     Two+                   36                                                       29.9 (10.3--58.1)
  Pancreatic    Not investigated      81                                                        ***Reference***                                      No investigations      82                                                           Reference
                Investigated          246                                          ***17***.***1 (−1***.***9--30***.***6)***                         One                    148                                                      4.8 (−14.4--16.7)
                                                                                                                                                     Two+                   97                                                       41.3 (20.2--62.5)
  Stomach       Not investigated      98                                                        ***Reference***                                      No investigations      104                                                          Reference
                Investigated          148                                          ***29***.***3 (14***.***0--45***.***8)***                         One                    112                                                       21.2 (6.2--35.8)
                                                                                                                                                     Two+                   30                                                       56.0 (16.7--107.8)

Abbreviations: CT=computed tomography; MRI=magnetic resonance tomography; NICE=National Institute for Health and Care Excellence.

^a^The numbers in these two groups (for all cancers) are slightly different as column 3 includes patients who have had any investigation in primary care, but counts in column 6 are based only on the five listed investigations (blood tests, chest X-rays, ultrasound, CT/MRI, or endoscopy).

Results presented in bold italics are those from [Table 4](#tbl4){ref-type="table"}

With a single exception (pancreatic cancer) primary-care investigations were associated with longer primary-care intervals. For colorectal, oesophageal, pancreatic and stomach cancer, primary-care intervals were longer among people who had two or more primary-care investigations, compared with those who had one. For lung and ovarian cancer. investigation use was associated with longer primary-care interval, but delay was not additionally longer among people with two or more primary-care investigations, compared with only one.

###### Sensitivity analysis using alternative parameterisation of clinical presentation (symptom category) or the NICE referral category

                                   **Number of cases**    **Adjusted for age, sex, and main (5) NICE referral categories based on presenting symptoms**   **Adjusting for age and sex and detailed (14) NICE referral categories**   **Adjusting age and sex and for clinical presentation using main presenting symptom**   **Adjusting for age and sex and for clinical presentation using main presenting symptom (allowing the effect of symptom to vary by age)**
  ------------- ------------------ --------------------- ----------------------------------------------------------------------------------------------- -------------------------------------------------------------------------- --------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------
  Colorectal    Not investigated   967                                                           ***Reference***                                                                         Reference                                                                         Reference                                                                                                         Reference
                Investigated       1144                                             ***25***.***7 (19***.***5--31***.***7)***                                                               24.6                                                                             26.5                                                                                                              26.2
  Ovarian       Not investigated   105                                                           ***Reference***                                                                         Reference                                                                         Reference                                                                                                         Reference
                Investigated       240                                              ***18***.***4 (12***.***2--25***.***5)***                                                               18.5                                                                             17.8                                                                                                              18.1
  Lung          Not investigated   294                                                           ***Reference***                                                                         Reference                                                                         Reference                                                                                                         Reference
                Investigated       1200                                             ***23***.***6 (16***.***8--30***.***0)***                                                               23.9                                                                             20.1                                                                                                              20.8
  Oesophageal   Not investigated   293                                                           ***Reference***                                                                         Reference                                                                         Reference                                                                                                         Reference
                Investigated       220                                              ***22***.***3 (13***.***2--32***.***4)***                                                               22.7                                                                             23.4                                                                                                              23.0
  Pancreatic    Not investigated   81                                                            ***Reference***                                                                         Reference                                                                         Reference                                                                                                         Reference
                Investigated       246                                              ***17***.***1 (−1***.***9--30***.***6)***                                                               14.9                                                                             13.9                                                                                                              16.0
  Stomach       Not investigated   98                                                            ***Reference***                                                                         Reference                                                                         Reference                                                                                                         Reference
                Investigated       148                                              ***29***.***3 (14***.***0--45***.***8)***                                                               28.4                                                                             27.7                                                                                                              28.0

Abbreviation: NICE=National Institute for Health and Care Excellence.

Results presented in bold italics are those from [Table 4](#tbl4){ref-type="table"}.

Different approaches to adjusting for clinical presentation in different ways have minimal impact on the association between primary-care investigation use and primary-care interval.

###### Supplementary analysis. The association between investigation use and referral interval (defined as period from day of referral to day when patient was first seen at hospital)

                                   **Primary-care interval**              **Referral interval**            **Pre-hospital interval**                              
  ------------- ------------------ --------------------------- ------------------------------------------- --------------------------- ------------------- ------ -------------------
  Colorectal    Not investigated   ***967***                                 ***Reference***               946                              Reference      946         Reference
                Investigated       ***1144***                      ***25***.***7 (19.5--31***.***7)***     1120                          5.1 (2.1--8.7)    1120    28.4 (21.9--34.9)
  Ovarian       Not investigated   ***105***                                 ***Reference***               101                              Reference      101         Reference
                Investigated       ***240***                    ***18***.***4 (12***.***2--25***.***5)***  236                           1.6 (−5.0--4.6)   238     18.7 (10.0--27.4)
  Lung          Not investigated   ***294***                                 ***Reference***               290                              Reference      290         Reference
                Investigated       ***1200***                   ***23***.***6 (16***.***8--30***.***0)***  1165                         4.5 (−1.6--10.1)   1165    28.6 (19.4--36.8)
  Oesophageal   Not investigated   ***293***                                 ***Reference***               283                              Reference      283         Reference
                Investigated       ***220***                    ***22***.***3 (13***.***2--32***.***4)***  215                          4.5 (−2.2--13.3)   215     29.1 (18.2--42.5)
  Pancreatic    Not investigated   ***81***                                  ***Reference***               78                               Reference      78          Reference
                Investigated       ***246***                    ***17***.***1 (−1***.***9--30***.***6)***  241                          −9.4 (−33.2--3.1)  241     7.4 (−15.6--30.3)
  Stomach       Not investigated   ***98***                                  ***Reference***               95                               Reference      95          Reference
                Investigated       ***148***                    ***29***.***3 (14***.***0--45***.***8)***  141                          11.9 (5.1--26.7)   141     41.8 (21.5--63.4)

Abbreviation: NICE=National Institute for Health and Care Excellence.

Results presented in bold italics are those from [Table 4](#tbl4){ref-type="table"}.
